Electronic Acknowledgement Receipt					
EFS ID:	2715319				
Application Number:	10524520				
International Application Number:					
Confirmation Number:	3426				
Title of Invention:	Use of antibodies against tumor-associated antigen				
First Named Inventor/Applicant Name:	Hans Loibner				
Customer Number:	2292				
Filer:	Leonard Richard Svensson/William Gorman				
Filer Authorized By:	Leonard Richard Svensson				
Attorney Docket Number:	4518-0108PUS1				
Receipt Date:	14-JAN-2008				
Filing Date:	31-OCT-2005				
Time Stamp:	20:13:32				
Application Type:	U.S. National Stage under 35 USC 371				

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$230
RAM confirmation Number	3940
Deposit Account	022448
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional fees required under 37 CFR 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Ch	. A alalitia a a l 🗆 a a a	was an ilina al ilina al a m OT	,	1 1 0 ·	(Document supply fees)
Unarge any	/ Additional Fees	reallirea linaer 37		iction i 191	HJOCHMENT SHIPPIV TEEST

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Mina-Harana Ingara Ingara	00000114Tusus susitival usulf	102691		1
	Miscellaneous Incoming Letter	20080114Transmittal.pdf	fbb3673bafecf1a7c3b9e1ca5d8a8cb5e ddf5d39	no	
Warnings:					
Information:					
2		20080114Amendment.pdf	976242	yes	13
		20000114Amenament.pai	c2c0195926362567516acf6aa985bda1 a2ac647c	yes	
	Multipa	rt Description/PDF files in	zip description		
	Document De	Start	End		
	Amendment - After No	1	1		
	Claims	2	7		
	Applicant Arguments/Remarks	8	13		
Warnings:					
Information:					
3	Extension of Time	20080114ExtensionOfTime.p	104249	no	1
		df df	fe3733ea4afb1ccdba69091c4000d1a9 2aeda86f		
Warnings:					
Information:					
4 Fee Worksheet (PTO-06)	Fee Worksheet (PTO-06)	20080114FeeTransmittal.pdf	120497	no	1
		d4661550a87da3bd92f65871702cef60 ed547ec7			
Warnings:					
Information:			,	,	
5 F	Fee Worksheet (PTO-06)	fee-info.pdf	8174	no	2
	. 55 17511.51.530 (1 1 5 5 5 7	.55	cdab0a2dec8f32dad0a7f99138a146ce 7d7e68ae	.10	
Warnings:					
Information:			.		
		Total Files Size (in bytes):	13	11853	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.